Neuren Pharmaceuticals completes enrolment for Phase II trial of trofinetide to treat Rett syndrome

US-based biopharmaceutical company Neuren has completed enrolment for its Phase II clinical trial of trofinetide in pediatric Rett syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news